



July Newsletter 2022

ClinTrial Refer - More Trials, More Options



Did you know that on average **28** trials are added to the ClinTrial Refer database **each month**? That means more options for patients across a growing number of health conditions.

The ClinTrial Refer community is growing and we are rapidly expanding our reach across Australia and helping a variety of clinical trial service providers communicate their trial activity to patients, carers, clinicians and anyone that is interested in learning more about current clinical trial options. We believe that open access is equity of access and everyone has a right to connect with options that could be life changing in the management of their health.

'I use ClinTrial Refer in my clinic, in MDT meetings or in my downtime when I am thinking about options patients might have. The beauty of the App is that it is accessible anywhere, anytime'


Associate Professor Nada Hamad, Staff Specialist and Director of Haematology Department, St Vincent's Hospital Sydney.

If you are a clinical trial service provider and would like to ensure your current trials can be accessed in the ClinTrial Refer platform please reach out to:
Christine Zahren - e: christine.zahren@health.nsw.gov.au

Stay tuned for some exciting announcements of new members joining the ClinTrial Refer community soon!

App Features - Other Details

Did you know that for each trial result you can find out if a trial has a 'tele-health' option and if you can self-refer or require a specialist referral? Check out the 'Other Details' section for more information.



To view additional trial information, select Other Details. This page will provide information about how to enrol, whether it is a tele-trial, whether the study is interventional or observational, the intervention type, healthy volunteer participation, and the type of disorder being studied.



Trial Spotlight

Scientific Title

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of ReoCure as Monotherapy and in Combination with Keytruda (Pembrolizumab) in Patients with Advanced Malignant Solid Tumours

The purpose of this study is to determine what dose of ReoCure, a virus that targets and kills cancer cells, is safe to use in humans.

Brief Summary

Who is it for?

You may be eligible for this study if you are an adult who has a confirmed advanced/late-stage solid tumour.

Study details:

Dose Escalation: Part A will test ReoCure at 3 different dose levels, Participants will receive 1 injection every 3 weeks in 3 Cohorts. Part B will test 2 dose levels of ReoCure in combination with a fixed dose of Pembrolizumab (200mg every 3 weeks) in 2 cohorts.

Dose Expansion: ReoCure in combination with a fixed dose of pembrolizumab (200 mg once in every 3 weeks) treated with the recommended dose selected from Dose Escalation part.

Blood, sputum, urine and faeces samples will be obtained for PK assessment before and after administration of study drug. Blood and urine will also be collected for clinical laboratory tests (haematology, clinical chemistry, blood coagulation and urinalysis), tumour marker evaluation and immunological response evaluation.

It is hoped that this study will determine the safest and most effective dose of ReoCure for those with advanced or late stage cancer, and help provide more insight in the effect of ReoCure.

Click [here](#) to view eligibility criteria and recruiting locations.

Nominations are open for the 2022 Research Australia Health and Medical Research Awards



For two decades, Research Australia's annual Health and Medical Research Awards have showcased and celebrated the country's finest health and medical research and

innovative minds.

This is an opportunity to shine a light on those who are working hard within our sector, making incredible discoveries and advancements, and who have tirelessly advocated and supported health and medical research.

Nominating is Easy – simply answer the four questions for selected category!

Members of Research Australia are now able to make their nominations across seven Award Categories.

- Peter Wills Medal
- Griffith University Discovery Award
- Philanthropy Award
- Frontiers Award Sponsored by Australian National University
- Data Innovation Award
- Health Services Research Award
- Advocacy Award

Click [here](#) to find out more about the awards criteria and how to nominate.

Nominations close Tuesday 9th August 2022.

Do you have something to share?

Share your story if you have taken part in a clinical trial or supported someone through a trial. Your stories and thoughts are important to us and can be a great inspiration to others. If you'd like to share a clinical trial story please email us at admin@clintrialreferapp.com. We'd love to hear from you.



ADDRESS

ClinTrial Refer c/o Ground Floor,
W R Pitney Building, St George Hospital,
Gray Street, KOGARAH 2217

EMAIL

www.clintrialrefer.org.au/

Australia

admin@clintrialreferapp.com

[Unsubscribe](#)

Copyright © *2019* *ClinTrial Refer*, All rights reserved.

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
ClinTrialRefer · St George Hospital · Gray Street · Kogarah, Nsw 2017 · Australia